Home · Healthcare M&A · Sell an Ambulatory Surgery Center in NJ

Specialty Practice M&A · 2026

Sell a Ambulatory Surgery Center in NJ

Ambulatory surgery centers (ASCs) are among the highest-multiple healthcare assets in NJ/NY in 2026. The shift from hospital-based to outpatient surgical care continues to accelerate, and PE-backed ASC platforms compete aggressively for NJ multi-specialty centers. Single-specialty ASCs (orthopedic, ophthalmology, GI, urology, pain) attract specialty-platform interest. Multi-specialty centers with diverse case mix and strong commercial payer concentration achieve premium auction dynamics. ASC sales involve more complex regulatory transitions than standard physician practice sales.

2026 NJ ambulatory surgery center multiples

NJ ambulatory surgery centers typically sell at 6×–10× EBITDA. The high end is driven by multi-specialty case mix, commercial-insurance concentration, physician utilization diversity, hospital JV structure, real estate ownership, modern facility infrastructure, and clean compliance history.

Sub-specialty / CategoryTypical Multiple
Multi-specialty ASC7×–10× EBITDA — broadest PE platform interest
Orthopedic-specialty ASC7×–9× EBITDA — driven by outpatient TJR shift
Ophthalmology-specialty ASC7×–9× EBITDA — cataract and refractive volume
GI-specialty (AEC / endoscopy)7×–9× EBITDA — endoscopy volume premium
Pain management ASC5×–7× EBITDA — payer-sensitive, more regulatory risk
Urology / women's health ASC6×–8× EBITDA

Active PE buyers acquiring NJ ambulatory surgery centers

Premium NJ ambulatory surgery center auctions in 2026 typically produce 3–6 competing LOIs from PE-backed platforms. Multi-platform competition is one of the most material drivers of final sale price — reaching the right buyers in the right sequence makes a measurable difference to net proceeds.

Key value drivers

Regulatory considerations for NJ/NY ambulatory surgery center sales

NJ ASCs operate under NJ Department of Health Class C / Class D ambulatory care facility licensure. Change-of-ownership reviews involve detailed facility, governance, and physician credentialing review — typical timeline 6–10 months. NY ASCs operate under Article 28 of Public Health Law — any 10%+ ownership change requires Certificate of Need (CON) approval through PHHPC. NY CON timeline runs 6–12+ months. Federal anti-kickback statute (AKS) and Stark Law structural considerations apply to physician ownership and referral arrangements; PE platforms use well-tested MSO structures to ensure compliance. CMS PECOS re-enrollment, Medicaid eMedNY (NY), and commercial payer credentialing must be coordinated.

Frequently asked questions

What multiple does a NJ ASC sell for in 2026?

NJ ASCs typically sell at 6×–10× EBITDA. Multi-specialty ASCs with strong commercial payer mix trade at the high end (8×–10×). Single-specialty ASCs (ortho, ophthalmology, GI) trade at 7×–9×. Pure cosmetic or elective-heavy ASCs vary widely based on payer mix and case stability.

Which ASC operators are acquiring in NJ in 2026?

SCA Health (Optum-owned, largest US ASC operator), USPI (Tenet), Surgery Partners (KKR-affiliated), AmSurg/Envision, Compass Surgical Partners, plus specialty-specific platforms (HOPCo for ortho, EyeCare Partners for ophthalmology, GI Alliance for endoscopy). Hospital systems (RWJBarnabas, Hackensack Meridian, Atlantic Health) acquire ASC stakes for site-of-service strategy.

How does NY Article 28 affect ASC sales?

NY ASCs operate under Article 28 of Public Health Law. Any 10%+ ownership change requires NY Department of Health Certificate of Need (CON) approval through PHHPC. CON review involves financial capability, character/competence, community need, and quality-of-care evaluation. Typical CON timeline 6–12+ months from filing. Total NY ASC sale timeline often runs 12–18 months.

What deal structures are common for NJ ASC sales?

Three common structures: (1) physician syndication — sell minority to PE platform, retain operational majority via JV; (2) full sale with employment continuity — sell 100% with selling physicians staying as employed surgeons; (3) roll-up into PE-backed multi-state platform — typically with rollover equity component (20–30% of total consideration).

Does Nexus Bridge charge upfront fees for ASC sales?

No. Success-only commission. You pay nothing until your ASC sells. Given ASC transaction complexity, we coordinate specialty legal counsel, regulatory transfer specialists, and Quality of Earnings advisors as part of the engagement.

How Nexus Bridge handles a ambulatory surgery center engagement

  1. Free 30-minute discovery call. Confidential conversation about your practice, target valuation, and sale timing. $0, no obligation.
  2. Free evidence-based valuation. Comparable transaction analysis using real NJ/NY/CT data. Delivered in writing within 7 days.
  3. Engagement letter signing. $0 upfront, success-only commission. 12-month exclusivity, 12-month named-buyer tail.
  4. Listing preparation. Financial normalization, CIM preparation, regulatory pre-screening specific to your specialty and state.
  5. Targeted buyer outreach. PE-platform engagement with the specific ambulatory surgery center buyers active in your sub-specialty.
  6. LOI negotiation and selection. Multiple LOIs negotiated in parallel where possible.
  7. Due diligence coordination. QoE, legal, regulatory, operational diligence managed in parallel.
  8. Regulatory transition. CON (NY Article 28), OMH (NY Article 31/MHOTRS), NJ DOH, CMS PECOS, Medicaid eMedNY, commercial payer credentialing managed against close.
  9. Close and post-close transition. Typically 8–14 months from listing to funded close depending on regulatory complexity.

Ready to discuss your ambulatory surgery center sale?

Schedule a free confidential 30-minute conversation. We'll review your practice profile, give you a realistic valuation range, and tell you which PE platforms or strategic acquirers fit your specific situation. $0 upfront, no obligation.

Related: Healthcare M&A NJ pillar · Sell an Orthopedic Practice · Sell an Ophthalmology Practice · Sell a GI Practice · Quality of Earnings Guide